机构：[1]Department of Integrated Traditional Chinese & Western Medicine, TheSecond Xiangya Hospital, Central South University, No .139 Middle RenminRoad, Changsha, Hunan 410011, People’s Republic of China[2]Department ofGeneral Surgery, The Second Xiangya Hospital, Central South University,Changsha 410011, Hunan, China[3]Department of Thoracic Medical Oncology,Hunan Cancer Hospital/the affiliated Cancer Hospital of Xiangya school ofMedicine, Central South University, Changsha 410013, Hunan, China[4]Department of Endocrinology, The First Affiliated Hospital of GuangzhouUniversity of Chinese Medicine, Guangzhou 510405, Guangdong, China
Enhancer RNAs (eRNAs) are demonstrated to be closely associated with tumourigenesis and cancer progression. However, the role of eRNAs in lung adenocarcinoma (LUAD) remains largely unclear. Thus, a comprehensive analysis was constructed to identify the key eRNAs, and to explore the clinical utility of the identified eRNAs in LUAD.First, LUAD expression profile data from the Cancer Genome Atlas (TCGA) dataset and eRNA-relevant information were integrated for Kaplan-Meier survival analysis and Spearman's correlation analysis to filtered the key candidate eRNAs that was associated with survival rate and their target genes in LUAD. Then, the key eRNA was selected for subsequent clinical correlation analysis. KEGG pathway enrichment analyses were undertaken to explore the potential signaling pathways of the key eRNA. Data from the human protein atlas (HPA) database were used to validate the outcomes and the quantitative real time-polymerase chain reaction (qRT-PCR) analysis was conducted to measure eRNA expression levels in tumor tissues and paired normal adjacent tissues from LUAD patients. Finally, the eRNAs were validated in pan-cancer.As a result, TBX5-AS1 was identified as the key eRNA, which has T-box transcription factor 5 (TBX5) as its regulatory target. KEGG analysis indicated that TBX5-AS1 may exert a vital role via the PI3K/AKT pathway, Ras signaling pathway, etc. Additionally, the qRT-PCR results and the HPA database indicated that TBX5-AS1 and TBX5 were significantly downregulated in tumour samples compared to matched-adjacent pairs. The pan-cancer validation results showed that TBX5-AS1 was associated with survival in four tumors, namely, adrenocortical carcinoma (ACC), LUAD, lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC). Correlations were found between TBX5-AS1 and its target gene, TBX5, in 26 tumor types.Collectively, our results indicated that TBX5-AS1 may be a potential prognostic biomarker for LUAD patients and promote the targeted therapy of LUAD.
基金：
the National Natural Science Foundation of
China (No.81873169) and Hunan Provincial Natural Science Foundation of
China (No. 2020JJ4803).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Integrated Traditional Chinese & Western Medicine, TheSecond Xiangya Hospital, Central South University, No .139 Middle RenminRoad, Changsha, Hunan 410011, People’s Republic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Cheng Lin,Han Tong,Chen Bolin,et al.TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.[J].BMC cancer.2021,21(1):794.doi:10.1186/s12885-021-08517-w.
APA：
Cheng Lin,Han Tong,Chen Bolin,Nie Kechao&Peng Weijun.(2021).TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma..BMC cancer,21,(1)
MLA：
Cheng Lin,et al."TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.".BMC cancer 21..1(2021):794
